Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

Dinutuximab Beta

  • Home
  • Dinutuximab Beta
Pilot Study: Busulfan-Based Haploidentical Stem Cell Transplantation Plus GD2 Antibody Therapy for High-Risk Neuroblastoma
Posted inHematology-Oncology news Pediatrics

Pilot Study: Busulfan-Based Haploidentical Stem Cell Transplantation Plus GD2 Antibody Therapy for High-Risk Neuroblastoma

Posted by MedXY By MedXY 06/04/2026
A small pilot study found that busulfan-based haploidentical stem cell transplantation followed by dinutuximab beta was feasible and may improve long-term remission in very high-risk neuroblastoma.
Read More
Optimizing Anti-GD2 Immunotherapy: Dinutuximab Beta Redefines Survival in Relapsed and High-Risk Neuroblastoma
Posted innews Oncology Pediatrics

Optimizing Anti-GD2 Immunotherapy: Dinutuximab Beta Redefines Survival in Relapsed and High-Risk Neuroblastoma

Posted by MedXY By MedXY 01/20/2026
Recent clinical trials establish dinutuximab beta as a cornerstone of neuroblastoma therapy, demonstrating significant survival benefits when combined with chemotherapy in relapsed cases, while clarifying that adding Interleukin-2 to standard consolidation increases toxicity without improving outcomes.
Read More
  • Long-Term Exposure to PM2.5 Constituents and Coronary Heart Disease Risk in China: A Comprehensive Review
  • Impact of Medically Tailored Groceries on Glycemic Control in Medicaid-Insured Adults with Type 2 Diabetes: Insights from a Randomized Controlled Trial
  • Digital Standardized Skin Care Regimen Enhances Outcomes in Patients with Acne-Rosacea Comorbidity: Insights from a Real-World Longitudinal Cohort
  • What Lies Beneath: Navigating Carotid Artery Depth for Safe Hemostatic Net Use in Facelift Surgery
  • Clarifying Dorsal Preservation Rhinoplasty: Insights and Classification from Over a Thousand Cases
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology health heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation MASLD mental health metformin Mortality myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prostate cancer public health quality of life randomized clinical trial randomized controlled trial randomized trial risk stratification SGLT2 inhibitors stroke type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in